Driver Mutations Dictate the Immunologic Landscape and Response to Checkpoint Immunotherapy of Glioblastoma
Alan T. Yeo(Boston University), Al Charest(Beth Israel Deaconess Medical Center), Frederick S. Varn(Jackson Laboratory), Rinku Pal(Beth Israel Deaconess Medical Center), Roel G.W. Verhaak(University of New Haven), Tuoye Xu(Beth Israel Deaconess Medical Center), Shruti Rawal(Brigham and Women's Hospital), Vicky A. Appleman(Takeda (United States)), Hemant Varma(Beth Israel Deaconess Medical Center), Joon Yoon(Harvard University), Christopher M. Rose(Genetic Technologies (Australia)), Steven P. Gygi(Harvard University), Rushil Shah(Nationwide Children's Hospital), Piyan Zhang(Beth Israel Deaconess Medical Center), Konstantinos Aliazis(Beth Israel Deaconess Medical Center), Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center)
Cited by 21
Related Papers
Inferring tumour purity and stromal and immune cell admixture from expression data
|Nature Communications|2013|10.7k
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k
Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma
|Cell|2016|2.4k
A quantitative atlas of mitotic phosphorylation
|Proceedings of the National Academy of Sciences|2008|1.6k